Aenova opens new building in Regensburg
The Aenova Group has opened a new production building for the manufacture of highly potent medicines for the treatment of cancer, amongst other things, at the Regensburg location for €25 million. The traditional pharmaceutical location in the Regensburg Bioregion will therefore be further expanded to be able to meet the worldwide increased market demand for highly efficacious medicines.
Supply bottlenecks for certain medicines have dominated the German media for months. One of the most modern production buildings for cytotoxics and cytostatics, both highly effective active pharmaceutical substances for cancer, has now been opened at the Aenova location in Regensburg. To meet the steadily increasing demand, Aenova, the world's leading development service provider and contract manufacturer for the pharmaceutical and healthcare industry, has expanded the Regensburg site for around €25 million with a new building for the development and production of highly potent active substances.
Regensburg has traditionally been a manufacturing location for the pharmaceutical industry for over 100 years. The Aenova site has its roots in the Heyden chemical works which was acquired by Bristol Myers Squibb in the 1950s. With the closure of the plant in the mid-1990s, today's contract and job order manufacturing began. Today, the Aenova Group is one of the world's leading contract manufacturers and development service providers for the pharmaceutical and healthcare industries. The services include the end-to-end production and development of all dosage forms, product groups and classes of active substances from drugs to dietary supplements. Around 4,000 employees work for the Aenova Group at 14 locations in Europe and the USA. The number of employees at the Regensburg location has been increasing for years, most recently around 400 people were employed here and produce over 1 billion tablets and capsules a year.
In Regensburg, the company develops and produces drugs for the treatment of inflammatory diseases such as psoriasis or arthritis, as well as for autoimmune diseases and cancer such as leukemia, as well as novel drugs (so-called New Chemical Entities, NCE). What is special about many of these medicines is their high efficacy, which means that the active substances already have the desired effect in the smallest doses, but special safety standards must therefore also be observed during development and production. "We in Regensburg are part of the Aenova Group "Competence Center HPAPI & Oncology Products". The new building is an important milestone in this respect,” explained Oliver Schmied, Managing Director at the Aenova site in Regensburg. "In this way, we can not only serve market needs and customer inquiries better, but above all we can reliably provide vital medicines for cancer patients worldwide. We are very proud of that here."
With the founding of BioPark Regensburg in 1999, Aenova became an important partner in the Regensburg Bioregion cluster. The company maintains a variety of connections to the University of Regensburg and is an important player in public relations, e.g. at events such as the “long night of sciences”. To promote young scientists, Aenova is a founding member of the MINT-Labs Regensburg e.V., an extracurricular place of learning in the city of Regensburg, in which children and young people become enthusiastic about mathematics, computer science, natural sciences and technology (MINT).
Official opening of the new laboratory building (Copyright Aenova Group) From left: Tim Bauer, Chief People Officer of the Aenova Group, Regensburg's Mayor Gertrud Maltz-Schwarzfischer, Oliver Schmied (Managing Director Aenova Regensburg), Dietmar Rohleder (Prange Group). (Photo: Aenova)
For further information see: